A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis

Trial Profile

A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Tocilizumab (Primary) ; Adalimumab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ADACTA
  • Sponsors Roche
  • Most Recent Events

    • 16 Jun 2018 Results of pooled post-hoc analysis from four studies (AMBITION, ACT-RAY, ADACTA and FUNCTION) presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 08 Nov 2017 Results of post hoc analysis assessing DAS28dcrit response presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top